A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

Phase 2 Completed 330 enrolled Epix Pharmaceuticals, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.

Timeline

Start: 2007-03
Primary completion: —
Completion: 2007-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NALUZOTAN	Small molecule	120 mg	—

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

Summary

Timeline

Drugs

Indications